The in vitro susceptibilities of three Pseudomonas species (Pseudomonas aeruginosa, Pseudomonas putida, and Pseudomonas fluorescens) and Xanthomonas maltophilia to quinolone antimicrobial agents were determined. Several newer agents, particularly PD117558, PD117596, PD127391, sparfloxacin (AT-4140), A-56620, and temafloxacin, were active against Pseudomonas species. X. maltophilia isolates were generally less susceptible than were Pseudomonas isolates but were inhibited by some of the newer quinolones.
Patients with cancer frequently develop infections, particularly when they are neutropenic. Pseudomonas aeruginosa is one of the gram-negative organisms most frequently isolated from such patients (4) . In recent years, other Pseudomonas species, such as Pseudomonas putida and Pseudomonas fluorescens, have begun to emerge as important nosocomial pathogens in cancer patients (1) . The same is true for Xanthomonas maltophilia. These organisms are capable of causing life-threatening infections such as bacteremia and pneumonia and are often multidrug resistant and difficult to eradicate (13) . The past few years have seen the development of a large number of 4-quinolone agents, some of which have been evaluated for the prevention and treatment of infections in cancer patients (7, 14) . We determined the in vitro activities of 14 newer quinolones against 118 clinical isolates of various Pseudomonas spp. and X. maltophilia.
Susceptibility testing was performed on 40 isolates of P. aeruginosa, 38 isolates of X. maltophilia, and 20 isolates each of P. putida and P. fluorescens. All of these organisms were obtained from blood culture specimens of cancer patients being treated at our institution during the past 5 years. Identification of the Pseudomonas spp. and X. maltophilia was accomplished with various biochemical tests by the methods outlined by Gilardi (6) . Organisms are stored in our laboratory by ultrafreezing methods, and older isolates are discarded as newer ones become available. All antimicrobial agents were obtained from their respective manufacturers in the form of standard laboratory powders and were stored at -70°C before use. Susceptibility testing was performed by a previously described microtiter broth dilution method and in accordance with guidelines established by the National Committee for Clinical Laboratory Standards (10, 13) . In brief, the organisms were incubated overnight in Mueller-Hinton broth, and appropriate dilutions were made so that the final inoculum tested was 105 CFU/ml. Antibiotic concentrations were prepared manually in cation-supplemented (Ca2+, 50 mg/liter; Mg2+, 25 mg/liter) MuellerHinton broth and dispensed automatically with an MIC-2000 dispenser (Dynatech Laboratories, Inc., Alexandria, Va.).
The range of antibiotic concentrations tested was 64.0 to 0.03 ,ug/ml. The MIC was described as the lowest concen-* Corresponding author. tration of drug that prevented visible growth after 18 h of incubation at 35°C. Staphylococcus aureus ATCC 25932 and Escherichia coli ATCC 25922 were included as control organisms for each procedure to ensure the validity of the results.
The in vitro activities of the various quinolones are summarized in Table 1 . Isolates of P. fluorescens and P. putida were generally more susceptible than were isolates of P. aeruginosa. The agents most active against P. fluorescens were ciprofloxacin (MIC, 0.25 jxg/ml) and PD117596 and PD127391 (MIC of each, 0.5 ,ug/ml). Temafloxacin, enoxacin, and A-56620 were also fairly active, inhibiting 90% of isolates at a concentration of 1.0 ,ug/ml. These drugs were also among the most active against P. putida isolates. Sparfloxacin (AT-4140), a recently developed 4-quinolone, also inhibited 90% of these isolates at a concentration of 1.0 ,g/ml. Against P. aeruginosa only PD117596 and PD127391 (MIC of each for 90% of isolates, 0.12 ,ug/ml) and ciprofloxacin (MIC for 90% of isolates, 0.5 ,ug/ml) had good activities.
X. maltophilia isolates were much less susceptible to most agents tested. Again, PD117596, PD127391, and PD117558 were the most active agents, with sparfloxacin, A-56620, and temafloxacin being moderately active. Ciprofloxacin inhibited less than 30% of the isolates at a concentration of 1.0 ,ug/ml.
Not much is known about the susceptibilities of many of the non-P. aeruginosa Pseudomonas species to newer antimicrobial agents, since these organisms are infrequently isolated from clinically important sites and many laboratories do not identify them to the species level. They are, however, being recovered more often from neutropenic cancer patients. It is therefore important to be aware of the susceptibilities of these organisms, particularly to newer agents, such as the 4-quinolones, which are being used or have the potential of being used for the prevention and treatment of infections in cancer patients. Other investigators have demonstrated the activities of some of the 4-quinolones against various Pseudomonas species, with ciprofloxacin generally being the most active agent of the ones currently available for clinical use (3, 9) . However, either the species tested were not specified or the number of isolates tested was very small. Our data are in agreement with those of other investigators regarding the relatively moderate activity of the 4-quinolones against X. maltophilia (2, 5). The three new Parke-Davis quinolones (PD117558, PD117596, and PD127391) appear to be more promising against X. maltophilia, and recently, another new quinolone, AM-1091, was shown to be active against these isolates, with an MIC for 90% of isolates of 0.5 ,ug/ml (8, 11, 12 
